Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 348

1.

Effect of low- and intermediate-purity clotting factor therapy on progression of human immunodeficiency virus infection in congenital clotting disorders. Transfusion Safety Study Group.

Gjerset GF, Pike MC, Mosley JW, Hassett J, Fletcher MA, Donegan E, Parker JW, Counts RB, Zhou Y, Kasper CK, et al.

Blood. 1994 Sep 1;84(5):1666-71.

2.

CD4 cells in HIV-1 infected hemophiliacs: effect of factor VIII concentrates.

Goldsmith JM, Deutsche J, Tang M, Green D.

Thromb Haemost. 1991 Oct 1;66(4):415-9.

PMID:
1839091
3.

[The effect of the type of factor VIII concentrate on the CD4 lymphocyte count in hemophiliacs with human immunodeficiency virus infection: the results of a meta-analysis].

Montoro Ronsano JB, Oliveras Martín J, Tusell Puigbert JM.

Med Clin (Barc). 1994 Nov 26;103(18):690-4. Spanish.

PMID:
7808075
4.
6.

Factor VIII concentrates in HIV-1-positive hemophiliacs--is pure better?

Eichinger S, Pabinger I, Kyrle PA, Köller U, Kier P, Schneider B, Lechner K.

Haemostasis. 1992;22(1):25-31.

PMID:
1521824
7.

Effect on lymphocyte subsets of clotting factor therapy in human immunodeficiency virus-1-negative congenital clotting disorders. The Transfusion Safety Study Group.

Hassett J, Gjerset GF, Mosley JW, Fletcher MA, Donegan E, Parker JW, Counts RB, Aledort LM, Lee H, Pike MC.

Blood. 1993 Aug 15;82(4):1351-7.

8.

The effect of monoclonal or ion-exchange purified factor VIII concentrate on HIV disease progression: a prospective cohort comparison.

Hay CR, Ludlam CA, Lowe GD, Mayne EE, Lee RJ, Prescott RJ, Lee CA.

Br J Haematol. 1998 Jun;101(4):632-7.

PMID:
9674733
9.

Spectrum of HIV infection and AIDS in a cohort of Italian hemophiliacs.

Sorice F, Ghirardini A, Martino P, Pasqualetti D, Annino L, Micozzi A, Cirelli A, Tamburrini E, Isacchi G, Buttò S, et al.

Haematologica. 1989 Mar-Apr;74(2):149-54.

PMID:
2568323
10.

Use of heat-treated clotting-factor concentrates in patients with haemophilia and a high exposure to HTLV-III.

McGrath KM, Thomas KB, Herrington RW, Turner PJ, Taylor L, Ekert H, Schiff P, Gust ID.

Med J Aust. 1985 Jul 8;143(1):11-3.

PMID:
2989666
11.

Effect of age on human immunodeficiency virus type 1-induced changes in lymphocyte populations among persons with congenital clotting disorders. Transfusion Safety Study Group.

Fletcher MA, Mosley JW, Hassett J, Gjerset GF, Kaplan J, Parker JW, Donegan E, Lusher JM, Lee H.

Blood. 1992 Aug 1;80(3):831-40.

12.

CD4+ counts before and after switching to monoclonal high-purity factor VIII concentrate in HIV-infected haemophilic patients.

Sabin C, Pasi J, Phillips A, Elford J, Janossy G, Lee C.

Thromb Haemost. 1994 Aug;72(2):214-7.

PMID:
7831654
13.

[Hemophiliacs with HIV. Slower progression of the infection among younger patients and at higher dosages of factor concentrates].

Astermark J, Berntorp E, Stigendal L, Johnsson H.

Lakartidningen. 1998 Jan 7;95(1-2):48-50. Swedish.

PMID:
9458646
14.

Immunological effects of intermediate purity clotting factor concentrates: failure to affect lymphocyte activation in vivo.

Higgins JA, Giangrande PL, Kernoff PB, Goodall AH.

Br J Haematol. 1993 Feb;83(2):296-305.

PMID:
8457478
15.

Immunological studies in HIV seronegative haemophiliacs: relationships to blood product therapy.

Cuthbert RJ, Ludlam CA, Steel CM, Beatson D, Peutherer JF.

Br J Haematol. 1992 Mar;80(3):364-9.

PMID:
1581216
16.

Immune status of human immunodeficiency virus seropositive and seronegative hemophiliacs infused for 3.5 years with recombinant factor VIII. The Kogenate Study Group.

Mannucci PM, Brettler DB, Aledort LM, Lusher JM, Abildgaard CF, Schwartz RS, Hurst D.

Blood. 1994 Apr 1;83(7):1958-62.

17.

An association between clotting factor concentrates use and mortality in human immunodeficiency virus-infected hemophilic patients.

Montoro JB, Oliveras J, Lorenzo JI, Tusell JM, Altisent C, Molina R, Ayestarán AI.

Blood. 1995 Sep 15;86(6):2213-9.

18.

[Hemophilia and HTLV-III infection].

Lechler E.

Z Hautkr. 1986 Dec 1;61(23):1687-704. German.

PMID:
2949442
19.

Treatment type and amount influenced human immunodeficiency virus seroprevalence of patients with congenital bleeding disorders.

Gjerset GF, Clements MJ, Counts RB, Halvorsen AS, Thompson AR.

Blood. 1991 Sep 15;78(6):1623-7.

Supplemental Content

Support Center